Navigation Links
Protagonist Therapeutics Names David Liu Chief Scientific Officer
Date:5/30/2013

MENLO PARK, Calif., May 30, 2013 /PRNewswire/ -- Protagonist Therapeutics, Inc. today announced the appointment of David Y. Liu , Ph.D. as Chief Scientific Officer. A 26-year veteran of the biotechnology industry, Dr. Liu is a former Vice President of Research and a Corporate Officer at FibroGen Inc. with deep rooted knowledge and expertise in the fields of inflammation and fibrosis.

(Logo: http://photos.prnewswire.com/prnh/20130501/MM06086LOGO)

"David's impressive track-record in basic discovery, translational research and clinical development of drugs for inflammatory indications will serve Protagonist well as our company advances its novel peptides from  discovery to preclinical and clinical stage development for both our own pipeline and that of our collaborators," said Dinesh V. Patel , Ph.D., President and Chief Executive Officer of Protagonist Therapeutics. "We are very pleased to welcome him to the Protagonist management team."

David Y. Liu was most recently Chief Operating Officer and co-founder of Trenovus, Inc., as well as a strategic advisor to several other biotechnology companies.  Prior to that he spent more than seven years at FibroGen, Inc. with management responsibility for all therapeutic research and drug discovery, including interim leadership of the Clinical Development department. These efforts resulted in two first-in-class drugs currently in phase 3 clinical trials for the treatment of anemia and in phase 2 for the treatment of deep organ fibrosis. Prior to that, he spent 10 years as Director of Inflammation Research at Scios, Inc., now part of Johnson & Johnson. Dr. Liu's career began with Cetus Corporation (since acquired by Chiron and now Novartis), COR Therapeutics (since acquired by Millenium/Takeda). He additionally spent 10 years as an academic researcher at Brigham and Women's Hospital, Harvard Medical School and was Instructor and Assistant Professor in the Department of Medicine, Harvard Medical School. Dr. Liu received his Ph.D. in microbiology and immunology from Michigan State University. He has more than 80 publications and patent filings and has been involved in the filing of 17 INDs and NDAs for over 10 clinical indications.

"Protagonist is an emerging company with a vaildated technology platform that is now primed to transition their internal and collaborative assets from discovery to development of well differentiated peptide therapeutic agents," said Dr. Liu. "I look forward to joining their efforts to identify drug candidates poised to serve important medical needs and guide their timely progression through preclinical and clinical proof-of-concept."

About Protagonist Therapeutics
Protagonist Therapeutics is a U.S.-incorporated biotechnology company pursuing the discovery and development of disulfide-rich peptides (DRPs) as well differentiated alternatives to biologics, and also as new chemical entities (NCEs) against those targets and life threatening diseases for which ideal small molecule and/or biologic options are unavailable. DRPs are a proven chemical class of drugs with numerous examples of orally stable and injectable NCEs on the market and in various stages of clinical development. The company has a validated technology platform well suited to explore the full potential of the DRP scaffold class. It comprises of a purposefully built computational design environment, directed evolution approaches to prepare millions of molecules via phage libraries, and classical small molecule medicinal chemistry-type analoging and SAR development.

Protagonist is a spin-out of University of Queensland's Institute of Molecular Biosciences (IMB) and has discovery operations in Menlo Park, California USA and Brisbane, Queensland, Australia. For further information, please visit http://www.protagonist-inc.com.


'/>"/>
SOURCE Protagonist Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced today ... its e-clinical software solution of choice.  This latest ... possible value to their clients by offering a ... preferred relationship establishes nowEDC as the EDC platform ... MedSource,s full-service clients.  "nowEDC has long been a ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
Breaking Medicine News(10 mins):